HC Wainwright & Co. Initiates Coverage On DiaMedica Therapeutics with Buy Rating, Announces Price Target of $7
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has initiated coverage on DiaMedica Therapeutics with a Buy rating and set a price target of $7.
October 07, 2024 | 10:52 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has initiated coverage on DiaMedica Therapeutics with a Buy rating and a price target of $7, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $7 by HC Wainwright & Co. suggests a positive sentiment towards DiaMedica Therapeutics. This could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100